BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 22, 2020
View Archived Issues
X chromosome is finished
Read More
Metabolic reprogramming promotes ADPKD cystogenesis
Read More
Phase III data presented for SCT-800 in severe hemophilia A patients
Read More
AZP-2006 studied in phase II for progressive supranuclear palsy
Read More
TIE2 IgG monoclonal agonistic antibody PMC-403 stabilizes vessels to enhance antitumor therapy
Read More
First-in-human study examines CAR-37 T cells in relapsed/refractory CD37+ hematologic malignancies
Read More
Novel engineered mouse model of GvHD
Read More
Discovery of novel anti-ILT2 monoclonal antibody, BND-22
Read More
Agios Pharmaceuticals presents Mat2A inhibitors
Read More
Newave Pharmaceutical divulges Bcl-2 inhibitors
Read More
CytoDyn presents safety data from phase II COVID-19 trial of leronlimab
Read More
FutureChem identifies FOLH1-binding radiopharmaceuticals
Read More
FORMA Therapeutics synthesizes USP9X inhibitors
Read More
Shanghai Dude Medical Science and Technology discovers TRK inhibitors
Read More
IMM-124E shows neutralizing activity against SARS-CoV-2
Read More
First patient dosed in phase II study of taletrectinib in NSCLC with ROS1 fusion
Read More
FDA places partial clinical hold on PRS-343
Read More
Researchers develop mouse model for imaging of Ca2+ changes in platelets
Read More
TNFR2 agonistic and antagonistic antibodies developed at BioInvent for treating solid tumors
Read More
FDA approves Qutenza for neuropathic pain associated with DPN of the feet
Read More
Phase III Measure Up 2 study of Rinvoq in atopic dermatitis meets primary and secondary endpoints
Read More
CTA cleared for phase I/IIa study of LUNAR-COV19 vaccine candidate
Read More
Bristol-Myers Squibb begins phase I/II study of BMS-986315 in advanced solid tumors
Read More